Takeda

Daily Table is a non-profit grocery food store.

Harness Therapeutics is a biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®, which allow for precise upregulation of protein expression. This innovative technology provides a unique mechanism of action aimed at addressing challenging diseases, significantly broadening the druggable proteome. Harness Therapeutics focuses on central nervous system and ophthalmologic disorders but also sees potential applications across various therapeutic areas. By enhancing translation, their platform meets unmet medical needs and enables the creation of differentiated products that cannot be achieved with existing technologies.

Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive health conditions. The clinic offers a comprehensive approach by integrating a team of gastroenterologists, specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This collaborative team helps patients identify the root causes of their symptoms and develops personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. By prioritizing accessibility and patient experience, Oshi Health aims to improve clinical outcomes and enhance the overall quality of life for individuals suffering from gastrointestinal issues.

PSI provides life-saving information, products, and services to tackle some of the world’s most pressing health problems so that people can lead healthier, happier, and more productive lives.

Seed Global Health strengthens health education and delivery in places facing a dire shortage of health professionals by working with partner countries to meet their long-term health care human resource needs.

Bulungula Incubator is an NPO that aims to sustainably end poverty in a generation while enhancing community life and cohesiveness.

VillageReach is an international NGO headquartered in Seattle, WA with field offices located in Malawi and Mozambique, Africa. Through collaboration with public and private sector partners, VillageReach seeks to increase access to quality healthcare for the world most underserved communities, bringing life-saving innovations to scale and sustainability. VillageReach develops, tests and implements solutions that uniquely address barriers at the lower levels or last mile of healthcare delivery in low-resource communities including medicine availability, human resource constraints, data visibility and lack of infrastructure.

Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancer, hepatitis B virus (HBV), and age-related diseases. Founded in 2009 and headquartered in Suzhou, China, the company has established a diverse pipeline of drug candidates, including HQP1351, a BCR-ABL/KIT inhibitor targeting resistant mutations, and APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies. Additional candidates include APG-1252, aimed at restoring apoptosis in various solid tumors, and APG-115, which targets the MDM2-p53 interaction in solid tumors and lymphoma. Ascentage Pharma also develops APG-1387 for advanced solid tumors and chronic HBV infection, alongside other therapies for non-small-cell lung carcinoma and chronic lymphocytic leukemia. The company has entered into clinical collaborations to explore innovative treatment combinations, furthering its commitment to addressing challenging diseases in the oncology landscape.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

ISHI Health is an AI-powered virtual clinic that offers personalized care to heart failure and cardiometabolic patients.

Maia Oncology is a virtual onco-primary care clinic that focuses on providing comprehensive care for cancer patients and survivors. The clinic operates a platform designed to coordinate cancer care, tracking important patient outcomes such as hospitalizations, emergency room visits, and the emergence of new comorbidities. This approach helps patients manage the complexities and long-term effects associated with cancer treatment. By offering a supportive environment, Maia Oncology aims to enhance the navigation of treatment-related challenges and improve overall patient well-being.

EvolveImmune Therapeutics specializes in developing innovative immunotherapies aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. The company has created a unique immunobiological platform that enables sustained immune activation and precise targeting of tumor cells through engineered biologics. These first-in-category therapeutics focus on maximizing the therapeutic benefit while minimizing toxicity, setting them apart from conventional CD3 bispecific and other immune therapies. By leveraging a proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates that target various immune cell types, thereby enhancing treatment options for patients suffering from a range of conditions, particularly cancer and autoimmune disorders.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Larkspur Biosciences is a biotechnology company dedicated to developing precision immunotherapies aimed at improving cancer treatment outcomes. The company focuses on addressing how tumors manipulate the immune system, creating therapies tailored for specific molecularly defined patient groups. By targeting the critical interactions between tumors and the immune system, Larkspur's approach seeks to enhance patients' immune responses, particularly in colorectal cancer and other malignancies. This strategic focus aims to overcome existing challenges that allow tumors to evade immune detection and attack, thereby advancing the efficacy of cancer therapies.

OncoResponse Inc. is a Houston-based immuno-oncology company focused on discovering innovative cancer therapies through its proprietary human antibody platform. The company specializes in identifying fully human monoclonal antibodies that target high-value immuno-oncology targets, particularly those associated with immunosuppressive myeloid biology. By exploring the adaptive immune responses of cancer patients who have successfully undergone checkpoint inhibition, OncoResponse aims to develop therapeutic antibodies that can mitigate tumor microenvironment immunosuppression and enhance immune activation. This approach seeks to transform cold tumors into hot tumors, thereby improving treatment outcomes for cancer patients.

Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive health conditions. The clinic offers a comprehensive approach by integrating a team of gastroenterologists, specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This collaborative team helps patients identify the root causes of their symptoms and develops personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. By prioritizing accessibility and patient experience, Oshi Health aims to improve clinical outcomes and enhance the overall quality of life for individuals suffering from gastrointestinal issues.

Boston Community Pediatrics is the first nonprofit private pediatric practice bringing equity to pediatric healthcare in Boston. BCP is a new model of innovative pediatric healthcare that addresses the social determinants of health within a relationship-driven framework.

Breakthrough Greater Boston transforms urban education for students and teachers through its unique Students Teaching Students model. Through six years of intensive, tuition-free out-of-school-time programming for traditionally underserved middle and high school students.

Greater Chicago Food Depository they programs includes food pantries, soup kitchens, and shelters,

Food For Free improves access to healthy food through establishing innovative programming and partnerships to overcome barriers and strengthen the community food system.

The only focused effort of its kind, Project Scientist was developed to offer girls the essential support unique to each stage of a future scientists' life serving girls/women ages 4 to PhD age. Through extensive research on current trends and practices has built a robust & focused, three-phase, program pipeline to serve as a national model for advancing girls and women, of all ages, in their STEM interests and passions.

Common Threads offers psychotherapy, occupational therapy, and alternative school placement. Their purpose is to empower people with autism, mental health issues, and sensory challenges by providing them and their families with real assistance. They achieve this by providing a range of evidence-based, personalized therapeutic and educational programmes that are tailored to an individual's strengths, needs, and aspirations.

Marthas Table is a provider of healthy food and education for children of all ages.

Red Sox Foundation is a Red Sox Nation power that improves health, educational, and recreational opportunities for kids, families, veterans, and communities in need. As part of their commitment to creating a good influence in their communities, Boston Red Sox Owner John Henry, Chairman Tom Werner, President/CEO Emeritus Larry Lucchino, and the team's partners formed and supported the Red Sox Foundation immediately after assuming ownership.

American Forests offers services to restore threatened forest ecosystems and inspire people to value and protect urban and wildland forests. Their projects have restored hundreds of thousands of acres of wildlife habitat, protected vital watersheds, and sequestered millions of tons of greenhouse gases. They are advocates for expanding urban tree canopy and green space, and a key funder of urban forest initiatives that have transformed communities across the country.

Atlanta Community Food Bank serves food pantries, community kitchens, childcare centers, night shelters, and senior centers. The donors are manufacturers, wholesalers, retailers, brokers, restaurants, food drives, farmers, and individuals.

Georgia Organics invests in organic farmers and community allies to cultivate a resilient, local food movement.

Out Teach provides professional development for elementary school teachers.

The American Red Cross (ARC), also known as the American National Red Cross, is a humanitarian organization that provides emergency assistance, disaster relief, and education inside the United States. It is the designated U.S. affiliate of the International Federation of Red Cross and Red Crescent Societies. It is the largest single supplier of blood and blood products in the United States, collecting and processing approximately 40 percent of the blood supply and distributing it to about 2,600 hospitals and transfusion centers nationwide. The organization researches and tests to protect the safety of the blood supply. It was among the first to develop and implement testing for many infectious diseases including, HIV, hepatitis B and C viruses, West Nile virus, and Chagas disease. The ARC operates the nationwide hemovigilance program to examine donor and patient adverse reactions. Data from the program is used to enhance blood product quality and safety The ARC serves on key committees of AABB and other blood-related organizations, and works closely with the U.S. Food and Drug Administration (FDA). The American Red Cross was established in 1881 and is headquartered in Washington, District of Columbia with 39 immunohematology reference laboratories nationwide.

Urban Farming Institute is a learning facility offering integrative farming methods designed to improve indoor farming operations. It combines tested, patented technologies with expert support on a global scale, assisting urban farmers in the process of vertical farming and streamlining processes linked to indoor horticulture. To get people involved in growing food and creating a healthy community, it has as its aim to create and promote urban farming.

Acumen is a nonprofit venture fund that invests in early-stage companies bringing critical services like agriculture, clean energy, education, financial inclusion, healthcare and workforce development to low-income communities in 14 countries across East and West Africa, South Asia, Latin America, and the United States. Since 2001, Acumen invested $128 million in 128 companies that have transformed the lives of over 308 million low-income people.

Mama's Kitchen aims to offer nutritional assistance to San Diego individuals at risk of undernourishment because of serious conditions like HIV, cancer, congestive heart failure, type 2 diabetes, and chronic renal disease.

San Diego River Park Foundation is a nonprofit organization created in 2001 to improve the future of the historic San Diego River, as well as the residents of San Diego and its visitors.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach using Engenious vectors. These vectors are engineered to facilitate the delivery of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the need for stem cell collection or harmful pre-treatment procedures like chemotherapy. This unique capability allows Ensoma to administer therapies through a single injection, making it possible to deliver effective treatments in outpatient settings and areas with limited access to advanced healthcare systems. By streamlining the process of gene therapy, Ensoma aims to enhance the accessibility and curative potential of genomic medicine for patients with various diseases.

Nimbus Lakshmi operates as a wholly-owned subsidiary of Nimbus Therapeutics and offers tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858, an orally administered, selective allosteric inhibitor of TYK2, is currently undergoing assessment for its potential in treating various autoimmune diseases, following promising Phase 2b outcomes in psoriasis.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care while controlling healthcare costs. The company has created a point-of-care diagnostic device that specializes in blood coagulation testing, capable of measuring up to twelve reactions using a small volume of blood. This technology allows patients to perform tests in various settings, including at home, while traveling, or in critical care environments, eliminating the need for laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve the quality of life for individuals requiring regular monitoring of their health.

Zelluna Immunotherapy AS, founded in 2016 and based in Oslo, Norway, is a biopharmaceutical company dedicated to developing T-cell receptor (TCR) therapies for cancer treatment. The company aims to transform cancer therapy by creating TCR-based immunotherapies that can address various cancer types and patient needs. Zelluna's primary asset comprises a diverse portfolio of TCRs derived from patients who demonstrated long-term survival in peptide-based cancer vaccine trials conducted by Professor Gustav Gaudernack at the Norwegian Radium Hospital/Oslo University Hospital. Currently, several TCRs are in various stages of development. Zelluna is a member of the Oslo Cancer Cluster, an organization that fosters collaboration among stakeholders in cancer research and development, and is situated within the Oslo Cancer Cluster Innovation Park, adjacent to leading cancer treatment and research facilities.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.

Crohn's and Colitis Canada is a charitable group run entirely by volunteers dedicated to curing Crohn's disease and ulcerative colitis and enhancing the lives of children and adults who are affected by these conditions. Through research, patient programs, advocacy, and awareness, they are altering the lives of people with Crohn's or colitis. They lay the foundation for new and more effective treatments while also resulting in significant advances in the fields of genetics, gut microbes, inflammation, and cell repair.

Adaptate Biotherapeutics is a biotherapeutics company based in London, founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technology, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. The company's work holds the promise of significantly enhancing treatment options for patients, providing effective medical solutions for various immune-related conditions.

Integra Therapeutics is a developer of next-generation of gene editing tools to cure diseases.

Aptihealth is a behavioral health engagement company that focuses on enhancing access to mental health services for underserved populations. Its innovative platform integrates physical and behavioral healthcare by connecting patients, medical providers, and behavioral health specialists through proprietary screening, assessment, and treatment management protocols. This digital solution aims to streamline the care process, enabling personalized care delivery and facilitating effective communication among all parties involved. By leveraging technology, Aptihealth seeks to improve patient outcomes and promote faster recovery, ensuring that individuals receive the support they need to maintain better mental health over the long term.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Egle Therapeutics SAS is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing innovative immunotherapies that target immune suppressor regulatory T-cells (Tregs) for the treatment of oncology and autoimmune diseases. The company's research focuses on a proprietary drug pipeline that includes computationally designed IL-2 variants aimed at modulating Treg activity. This approach seeks to either engage or dis-engage Tregs, facilitating the development of therapies that can effectively combat cancer and other related conditions by addressing the immune suppression caused by Tregs. Egle Therapeutics aims to advance its unique portfolio to provide new treatment options in the healthcare field.

Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive health conditions. The clinic offers a comprehensive approach by integrating a team of gastroenterologists, specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This collaborative team helps patients identify the root causes of their symptoms and develops personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. By prioritizing accessibility and patient experience, Oshi Health aims to improve clinical outcomes and enhance the overall quality of life for individuals suffering from gastrointestinal issues.

Tele911 is a technology company focused on enhancing emergency medical services through its Tele911 Virtual Visit platform. This patient-centered emergency care solution integrates telemedicine and patient navigation to address the needs of stable patients, offering alternatives to unnecessary ambulance transports to hospital emergency rooms. By enabling emergency medical service providers to consult with patients remotely, Tele911 aims to improve patient care while simultaneously reducing costs within the healthcare system.

Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

Harness Therapeutics is a biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®, which allow for precise upregulation of protein expression. This innovative technology provides a unique mechanism of action aimed at addressing challenging diseases, significantly broadening the druggable proteome. Harness Therapeutics focuses on central nervous system and ophthalmologic disorders but also sees potential applications across various therapeutic areas. By enhancing translation, their platform meets unmet medical needs and enables the creation of differentiated products that cannot be achieved with existing technologies.

BridGene Biosciences is a biotechnology company focused on discovering and developing small molecules aimed at traditionally untreatable targets. The company employs advanced chemoproteomic technology, integrating covalent chemistry, chemical proteomics, and quantitative mass spectrometry to create highly selective small-molecule inhibitors. This innovative approach allows for proteome-wide screening in live cells, facilitating the identification of drug targets that have historically been considered undruggable. By leveraging these techniques, BridGene seeks to advance therapeutic development in the healthcare sector, ultimately contributing to the discovery of new drugs and improving treatment options.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Adaptate Biotherapeutics is a biotherapeutics company based in London, founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technology, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. The company's work holds the promise of significantly enhancing treatment options for patients, providing effective medical solutions for various immune-related conditions.

Arcellx is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with cancer and other incurable diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Its lead product candidate, CART-ddBCMA, targets relapsed or refractory multiple myeloma and is currently undergoing a Phase 1 clinical study. This therapy has received multiple designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is advancing its controllable CAR-T therapy, ARC-SparX, through two clinical programs aimed at treating relapsed or refractory multiple myeloma and acute myeloid leukemia.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, established in 2015. The company focuses on developing innovative adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Utilizing a proprietary platform that combines structural insights with accelerated evolution, StrideBio creates novel AAV capsids designed to evade neutralizing antibodies. This approach allows for enhanced gene addition, gene silencing, and gene editing capabilities, addressing the limitations of first-generation gene therapies. By engineering unique and differentiated vectors, StrideBio aims to improve treatment outcomes for patients facing devastating conditions.

Maverick Therapeutics, Inc. is a biotechnology company based in Brisbane, California, established in 2016. The company specializes in developing T-cell engagement therapeutics aimed at treating solid tumor cancers. Its innovative platform, COBRA™, is recognized as a leading bispecific T-cell engaging technology, designed to enhance safety and efficacy in cancer immunotherapy. This platform addresses toxicity challenges by ensuring that T-cell activity is inactive upon administration and becomes fully active only within the tumor microenvironment. By focusing on these advancements, Maverick Therapeutics aims to improve treatment outcomes and the overall quality of care for patients with cancer.

Presage has developed a means of assessing tumor response to drugs or RNA interference agents without the limitations inherent to systemic administration. The Presage clinical surrogate approach enables drug companies to halt development projects for compounds that show no efficacy in the native tumor microenvironment. In addition, the Presage approach can identify drug targets using RNA interference without concern regarding localization or distribution of systemically administered RNAi agents. Presage technology can also be used to identify effective drug combinations in ways that more directly measure the efficacy of such combinations than otherwise possible.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach using Engenious vectors. These vectors are engineered to facilitate the delivery of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the need for stem cell collection or harmful pre-treatment procedures like chemotherapy. This unique capability allows Ensoma to administer therapies through a single injection, making it possible to deliver effective treatments in outpatient settings and areas with limited access to advanced healthcare systems. By streamlining the process of gene therapy, Ensoma aims to enhance the accessibility and curative potential of genomic medicine for patients with various diseases.

Aspen RxHealth is a Tampa, Florida-based company that provides an online platform designed to connect licensed pharmacists with patients requiring enhanced medication services. Through its app-based technology, Aspen RxHealth facilitates direct patient care by matching pharmacists to patients based on various social and clinical criteria, such as language and medication regimens. This platform enables health plans and providers to link their patients with a community of pharmacists who can deliver clinical services tailored to individual needs. The services offered include comprehensive medication reviews and targeted medication interventions, all aimed at optimizing communication and improving patient care.

Catamaran Bio is a biotechnology company focused on developing allogeneic immune cell therapies, specifically CAR-NK cell therapies, aimed at treating solid tumors and other cancers. The company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf therapeutic products that can address significant unmet medical needs. Founded in 2019 and headquartered in Cambridge, Massachusetts, Catamaran Bio is committed to providing transformative treatments through genetic engineering of NK cells, enabling easier access for medical practitioners and patients in need of effective cancer therapies.

Bridge Medicines LLC is a biotechnology company based in New York, established in 2016. It specializes in drug discovery and the development of innovative therapeutics for various human diseases, particularly in oncology and rare diseases. The company collaborates with prominent institutions such as Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine, as well as industry partners like Takeda Pharmaceutical Company. Bridge Medicines focuses on advancing technologies from academic research through to clinical development, with a notable emphasis on developing inhibitors for acute leukemias and small molecule inhibitors for hereditary angioedema and inflammatory disorders. The initiative aims to provide comprehensive support throughout the drug development process, from validating preclinical studies to advancing candidates into human clinical trials.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

xFOREST Therapeutics specializes in a drug discovery platform focused on the efficient identification of RNA-targeting drugs. The company employs advanced technology that integrates parallel biochemical analysis systems to study various RNA structures, regardless of their source organ, species, or virus. This comprehensive approach allows for the rapid analysis of diverse nucleic acid species, contributing to the development of impactful and selective therapeutic solutions in the RNA-targeted drug space. Through its innovative in silico analysis pipelines, xFOREST Therapeutics aims to enhance the drug discovery process, ultimately benefiting patients by delivering targeted therapies.

Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive health conditions. The clinic offers a comprehensive approach by integrating a team of gastroenterologists, specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This collaborative team helps patients identify the root causes of their symptoms and develops personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. By prioritizing accessibility and patient experience, Oshi Health aims to improve clinical outcomes and enhance the overall quality of life for individuals suffering from gastrointestinal issues.

Palleon Pharmaceuticals is a biotechnology company that develops therapeutics targeting glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in creating glycoimmune checkpoint inhibitors, a novel class of drugs designed to enhance immune response against cancer. By integrating insights from global leaders in glycoscience and human immunology, Palleon aims to provide a broader array of combination therapies that not only address cancer but also combat resistance to traditional immuno-oncology treatments. Additionally, the company develops therapies for inflammatory diseases, including autoimmunity and fibrosis.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells specifically designed to target and treat solid tumors. By utilizing advanced technology, the company aims to create chimeric antigen receptor (CAR) T-cell therapies that exhibit tumor specificity, allowing them to induce cytotoxicity only when interacting with tumor cells while sparing healthy tissues. This selective targeting mitigates the safety risks commonly associated with existing CAR-T therapies, providing a promising approach to cancer treatment that enhances efficacy and reduces potential harm to noncancerous cells.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Amwell is a telehealth platform based in the United States that connects healthcare providers, insurers, patients, and innovators to enhance access to affordable and high-quality medical care. Founded in 2006 and headquartered in Boston, the company offers a comprehensive platform to address various telehealth needs, including urgent and acute care, post-acute care, chronic care management, and healthy living. With over a decade of experience, Amwell serves more than 240 health systems, comprising 2,000 hospitals and 55 health plan partners, and reaches over 150 million individuals, including 36,000 employers. The platform supports both on-demand and scheduled consultations, providing solutions for primary care, specialty consults, and chronic care programs like musculoskeletal and dermatology care.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Redpin Therapeutics is a preclinical stage gene therapy company based in New York, founded in 2017. The company specializes in developing a proprietary chemogenetics platform designed to create targeted cell therapies for intractable diseases of the nervous system. Its innovative approach combines principles from synthetic biology, gene therapy, and conventional pharmacotherapy, utilizing ion channels as neuromodulation tools. This enables selective activation or inhibition of disease-causing neurons, allowing for precise regulation of dysfunctional neuronal circuits while sparing healthy cells. Through its research and development efforts, Redpin Therapeutics aims to provide new treatment options for challenging neurological conditions.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

EmendoBio, Inc. is focused on advancing the field of genome editing by developing innovative gene editing tools aimed at overcoming challenges in gene therapy. The company leverages expertise in protein engineering and DNA repair, combining insights from top academic institutions to create genetic medicines that address currently untreatable disorders and diseases. By transforming existing methodologies and employing creative approaches, EmendoBio seeks to resolve significant bottlenecks in gene therapy, enabling healthcare professionals to provide effective treatments where none previously existed. Through a commitment to pushing scientific boundaries, EmendoBio strives to deliver on the potential of gene editing for transformative medical solutions.

EvolveImmune Therapeutics specializes in developing innovative immunotherapies aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. The company has created a unique immunobiological platform that enables sustained immune activation and precise targeting of tumor cells through engineered biologics. These first-in-category therapeutics focus on maximizing the therapeutic benefit while minimizing toxicity, setting them apart from conventional CD3 bispecific and other immune therapies. By leveraging a proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates that target various immune cell types, thereby enhancing treatment options for patients suffering from a range of conditions, particularly cancer and autoimmune disorders.

Harness Therapeutics is a biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®, which allow for precise upregulation of protein expression. This innovative technology provides a unique mechanism of action aimed at addressing challenging diseases, significantly broadening the druggable proteome. Harness Therapeutics focuses on central nervous system and ophthalmologic disorders but also sees potential applications across various therapeutic areas. By enhancing translation, their platform meets unmet medical needs and enables the creation of differentiated products that cannot be achieved with existing technologies.

Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.

Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive health conditions. The clinic offers a comprehensive approach by integrating a team of gastroenterologists, specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This collaborative team helps patients identify the root causes of their symptoms and develops personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. By prioritizing accessibility and patient experience, Oshi Health aims to improve clinical outcomes and enhance the overall quality of life for individuals suffering from gastrointestinal issues.

Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.

Arcellx is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with cancer and other incurable diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Its lead product candidate, CART-ddBCMA, targets relapsed or refractory multiple myeloma and is currently undergoing a Phase 1 clinical study. This therapy has received multiple designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is advancing its controllable CAR-T therapy, ARC-SparX, through two clinical programs aimed at treating relapsed or refractory multiple myeloma and acute myeloid leukemia.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

Axcelead Drug Discovery Partners specializes in drug discovery services that connect foundational scientific research to clinical development. The company offers a comprehensive range of services that span from exploratory research to the optimization of candidate compounds. With a focus on scientific excellence and strong intellectual property protection, Axcelead operates state-of-the-art facilities accredited for good laboratory practices (GLP). This integrated approach allows clients to leverage Axcelead's expertise and technologies in early drug discovery, facilitating a smoother transition from basic research to clinical applications.

Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

Bsense Bio Therapeutics develops small molecules for the treatment of sensory hyperexcitability related disorders. Bsense pioneers a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, to achieve greater efficacy and safety.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases. Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusive technology lowers the extra BCAA that is floating around.